ACP
JNCE

Acuta Capital Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Acuta Capital Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-813,500
Closed -$5.52M – 55
2022
Q1 		$5.52M Buy
813,500
+686,000
+538% +$4.89M 2.58% 14
2021
Q4 		$1.06M Buy
+127,500
New +$1.05M 0.45% 35

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Acuta Capital Partners's JNCE Position: Q2 2022 in Review

Acuta Capital Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 813,500 shares — an estimated $5.52M sold.

Acuta Capital Partners first reported a position in JNCE in Q4 2021 and held it in 2 quarters. The position peaked at $5.52M in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • Acuta Capital Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 813,500 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $5.52M.
  • Acuta Capital Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Acuta Capital Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $5.52M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.